Fig. 5: IP injections of ART5803 reverse abnormal behaviors induced by pathogenic autoantibody (#003-102 Ab) in marmoset disease model.

a Experimental design of ART5803 intraperitoneal (IP) injection efficacy study. Continuous ICV infusion of pathogenic #003-102 Ab (10 µg/h) into the third ventricle in marmosets for 3 weeks. Six days after ICV infusion of #003-102 Ab, marmosets showing robust abnormalities were divided into two treatment groups (Grouping on Day 6), ART5803 (n = 8) and control vehicle (n = 7) and dosed with either 400 mg/kg ART5803 or vehicle via IP twice a week for 2 weeks starting on Day 7. Over the course of the study, abnormal behaviors were evaluated using the abnormal rating scale. b Time course (days) of abnormal behaviors in marmosets with vehicle or ART5803 IP injections at Day 0, Day 6, Day 14 and Day 21. Each point is from an individual marmoset in the vehicle treated group (n = 7) and ART5803 treated group (n = 8), and bars represent mean ± SEM. Statistical analysis was performed using two-tailed, Wilcoxon matched-pairs signed rank test. *, p < 0.05; **, p < 0.01; ns = not significant. c Comparison of abnormal behaviors between ART5803 and vehicle IP injected groups at Day 0, Day 6, Day 14 and Day 21 of the study. Each point is from an individual marmoset and data are mean ± SEM of n = 7 (Pathogenic antibody + Vehicle) or n = 8 (Pathogenic antibody + ART5803). Statistical analysis was performed using unpaired, two-tailed, Student’s t-tests. *, p < 0.05; ns = not significant. Source data are provided in Supplementary Table S7.